抗中性粒细胞胞质抗体相关性血管炎继发间质性肺病的研究进展
Research Progress of Anti-Neutrophil Cytoplasmic Antibodies Associated Vasculitis Secondary Interstitial Lung Disease
摘要: 抗中性粒细胞胞质抗体(Anti-Neutrophil Cytoplasm Antibody, ANCA)相关性血管炎(Anti-neutrophil cytoplasmic Antibodies Associated Vasculitis, AAV)是结缔组织疾病(Connective Tissue Disease, CTD)相关的间质性肺疾病(Interstitial Lung Disease, ILD)的一种，因其发病机制尚且不能明确，诊断较为困难，复发率高等特点，目前仍需要进一步研究，本文将从近年来AAV-ILD的发病机制、血清标志物及治疗等方面的研究进展进行系统性论述。
Abstract: Anti-neutrophil cytoplasmic antibodies associated vasculitis is a kind of interstitial lung disease related to connective tissue diseases. Due to its unclear pathogenesis, difficult diagnosis and high recurrence rate, further research is still needed. This paper will systematically discuss the patho-genesis, serum markers and treatment of AAV-ILD in recent years.
文章引用：席磊, 白祥梅, 杨柳, 王玲. 抗中性粒细胞胞质抗体相关性血管炎继发间质性肺病的研究进展[J]. 临床医学进展, 2023, 13(3): 3018-3024. https://doi.org/10.12677/ACM.2023.133428

参考文献

[1] American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) Was Adopted by the ATS Board of Directors, June 2001 and by the ERS Executive Committee, June 2001. American Journal of Respiratory and Critical Care Medicine, 165, 277-304.
[2] Liu, G.Y., Ventura, I.B., Achtar-Zadeh, N., et al. (2019) Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients with Idiopathic Pulmonary Fibrosis. Chest, 156, 715-723. [Google Scholar] [CrossRef] [PubMed]
[3] Maillet, T., Goletto, T., Beltramo, G., et al. (2020) Usual Inter-stitial Pneumonia in ANCA-Associated Vasculitis: A Poor Prognostic Factor. Journal of Autoimmunity, 106, Article ID: 102338. [Google Scholar] [CrossRef] [PubMed]
[4] Kim, S.M., Choi, S.Y., Kim, S.Y., et al. (2019) Clinical Characteristics of Patients with Vasculitis Positive for Anti-Neutrophil Cytoplasmic Antibody Targeting both Proteinase 3 and Myeloperoxidase: A Retrospective Study. Rheumatology International, 39, 1919-1926. [Google Scholar] [CrossRef] [PubMed]
[5] Sada, K.E., Yamamura, M., Harigai, M., et al. (2014) Classi-fication and Characteristics of Japanese Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Nationwide, Prospective, Inception Cohort Study. Arthritis Research & Therapy, 16, R101. [Google Scholar] [CrossRef] [PubMed]
[6] 张俊, 李弋南, 孙雪娟, 等. 中国东南部地区某市抗中性粒细胞胞质抗体相关血管炎流行病学的回顾性调查[J]. 中国医药指南, 2020, 18(16): 1-5.
[7] Chen, M. and Kallenberg, C.G. (2010) ANCA-Associated Vasculitides—Advances in Pathogenesis and Treatment. Nature Reviews Rheumatology, 6, 653-664. [Google Scholar] [CrossRef] [PubMed]
[8] Chrysanthopoulou, A., Mitroulis, I., Apostolidou, E., et al. (2014) Neutrophil Extracellular Traps Promote Differentiation and Function of Fibroblasts. The Journal of Pathology, 233, 294-307. [Google Scholar] [CrossRef] [PubMed]
[9] Negreros, M. and Flores-Suarez, L.F. (2021) A Proposed Role of Neutrophil Extracellular Traps and Their Interplay with Fibroblasts in ANCA-Associated Vasculitis Lung Fibrosis. Autoimmunity Reviews, 20, Article ID: 102781. [Google Scholar] [CrossRef] [PubMed]
[10] Chen, M., Jayne, D. and Zhao, M.H. (2017) Complement in ANCA-Associated Vasculitis: Mechanisms and Implications for Management. Nature Reviews Nephrology, 13, 359-367. [Google Scholar] [CrossRef] [PubMed]
[11] Lubbers, R., van Essen, M.F., van Kooten, C., et al. (2017) Production of Complement Components by Cells of the Immune System. Clinical and Experimental Immunology, 188, 183-194. [Google Scholar] [CrossRef] [PubMed]
[12] Mukherjee, M., Thomas, S.R., Radford, K., et al. (2019) Sputum Antineutrophil Cytoplasmic Antibodies in Serum Antineutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 199, 158-170. [Google Scholar] [CrossRef] 
[13] Borie, R. and Crestani, B. (2018) Antineutrophil Cytoplasmic Antibody-Associated Lung Fibrosis. Seminars in Respiratory and Critical Care Medicine, 39, 465-470. [Google Scholar] [CrossRef] [PubMed]
[14] Sacoto, G., Boukhlal, S., Specks, U., et al. (2020) Lung Involvement in ANCA-Associated Vasculitis. La Presse Médicale, 49, Article ID: 104039. [Google Scholar] [CrossRef] [PubMed]
[15] Doring, Y., Soehnlein, O. and Weber, C. (2017) Neutrophil Ex-tracellular Traps in Atherosclerosis and Atherothrombosis. Circulation Research, 120, 736-743. [Google Scholar] [CrossRef] 
[16] Gehrig, S., Duerr, J., Weitnauer, M., et al. (2014) Lack of Neutrophil Elastase Reduces Inflammation, Mucus Hypersecretion, and Emphysema, but Not Mucus Obstruction, in Mice with Cystic Fibrosis-Like Lung Disease. American Journal of Respiratory and Critical Care Medicine, 189, 1082-1092. [Google Scholar] [CrossRef] 
[17] Koening, C.L. and von Hennigs, I. (2021) Antineutrophil Cytoplasmic Antibody (ANCA) Vasculitis: Pathophysiology, Diagnosis, and the Evolving Treatment Landscape. The American Journal of Managed Care, 27, S267-S276. [Google Scholar] [CrossRef] [PubMed]
[18] 孙忻, 高粹, 黄警, 等. 肺间质病患者血清抗中性粒细胞胞质抗体阳性的临床意义及研究进展[J]. 中华结核和呼吸杂志, 2019(7): 526-529.
[19] Shogo, M., Takuya, K., Hiroko, K., et al. (2021) CCL2 Produced by CD68+/CD163+ Macrophages as a Promising Clinical Biomarker of Microscopic Polyangiitis-Interstitial Lung Disease. Rheumatology (Oxford, England), 60, 4643-4653. [Google Scholar] [CrossRef] [PubMed]
[20] Mosakowska, M., Kania, D.B., Szamotulska, K., et al. (2021) Assessment of the Correlation of Commonly Used Laboratory Tests with Clinical Activity, Renal Involvement and Treatment of Systemic Small-Vessel Vasculitis with the Presence of ANCA Antibodies. BMC Nephrology, 22, 290. [Google Scholar] [CrossRef] [PubMed]
[21] Bao, Y., Zhang, W., Shi, D., et al. (2021) Correlation between Serum Tumor Marker Levels and Connective Tissue Disease-Related Interstitial Lung Disease. International Journal of General Medicine, 14, 2553-2560. [Google Scholar] [CrossRef] 
[22] Xu, F. (2016) Association of Serum Tumor Markers with Interstitial Lung Disease in Patients with or without Connective Tissue Disease: A Cross-Sectional Study.
[23] 谭立明, 卢晓霞, 张倩, 等. 血清KL-6、DD及CRP在ANCA相关性血管炎合并间质性肺病检测中的临床价值[J]. 中国免疫学杂志, 2021(8): 983-987.
[24] Elhai, M., Avouac, J. and Allanore, Y. (2020) Circulating Lung Biomarkers in Idiopathic Lung Fibrosis and Interstitial Lung Diseases Associated with Connective Tissue Diseases: Where Do We Stand? Sem-inars in Arthritis and Rheumatism, 50, 480-491. [Google Scholar] [CrossRef] [PubMed]
[25] Geetha, D. and Jefferson, J.A. (2020) ANCA-Associated Vasculitis: Core Curriculum 2020. American Journal of Kidney Diseases, 75, 124-137. [Google Scholar] [CrossRef] [PubMed]
[26] Lourdudoss, C. and Vollenhoven, R. (2014) Mycophenolate Mofetil in the Treatment of SLE and Systemic Vasculitis: Experience at a Single University Center. Lupus, 23, 299-304. [Google Scholar] [CrossRef] [PubMed]
[27] Young, H.L. and Gwan, G.S. (2021) Com-parative Efficacy and Safety of Rituximab, Mycophenolate, and Cyclophosphamide in Active Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. International Journal of Clinical Pharmacology and Therapeutics, 59, 645-653. [Google Scholar] [CrossRef] 
[28] Sharon, A.C., Carol, A.L., Mehrdad, M., et al. (2021) 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Anti-body-Associated Vasculitis. Arthritis Care & Research, 73, 1366-1383.
[29] Wallace, Z.S. and Miloslavsky, E.M. (2020) Management of ANCA Associated Vasculitis. BMJ, 368, m421. [Google Scholar] [CrossRef] [PubMed]
[30] Rona, M.S., Rachel, B.J., Ulrich, S., et al. (2020) Rituximab as Therapy to Induce Remission after Relapse in ANCA-Associated Vasculitis. Annals of the Rheumatic Diseases, 79, 1243-1249.
[31] Nathan, S.D., Albera, C., Bradford, W.Z., et al. (2017) Effect of Pirfenidone on Mortality: Pooled Analyses and Meta-Analyses of Clinical Trials in Idiopathic Pulmonary Fibrosis. The Lancet Respiratory Medicine, 5, 33-41. [Google Scholar] [CrossRef] 
[32] Shah, P.V., Balani, P., Lopez, A.R., et al. (2021) A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases. Cureus, 13, e12482. [Google Scholar] [CrossRef] [PubMed]
[33] Song, J.W., Ogura, T., Inoue, Y., et al. (2020) Long-Term Treatment with Nintedanib in Asian Patients with Idiopathic Pulmonary Fibrosis: Results from INPULSIS(R)-ON. Respirology, 25, 410-416. [Google Scholar] [CrossRef] [PubMed]
[34] Wijsenbeek, M. and Cottin, V. (2020) Spectrum of Fibrotic Lung Diseases. The New England Journal of Medicine, 383, 958-968. [Google Scholar] [CrossRef] 

为你推荐